Table 1.
Patient Characteristics
| (Row percentages) | ypN0 N=411 (76.3%) |
ypN+ N=128 (23.7%) |
Total N=539 |
P-value |
|---|---|---|---|---|
| Trial | 0.261 | |||
| CALGB 40601 | 163 (73.8%) | 58 (26.2%) | 221 | |
| CALGB 40603 | 248 (78.0%) | 70 (22.0%) | 318 | |
| Treatment arm | 0.0131 | |||
| Paclitaxel | 65 (83.3%) | 13 (16.7%) | 78 | |
| Paclitaxel and Bevacizumab | 52 (66.7%) | 26 (33.3%) | 78 | |
| Paclitaxel and Carboplatin | 65 (79.3%) | 17 (20.7%) | 82 | |
| Paclitaxel, Carboplatin and Bevacizumab | 66 (82.5%) | 14 (17.5%) | 80 | |
| Paclitaxel and Trastuzumab | 66 (74.2%) | 23 (25.8%) | 89 | |
| Paclitaxel, Trastuzumab and Lapatinib | 68 (81.0%) | 16 (19.0%) | 84 | |
| Paclitaxel and Lapatinib | 29 (60.4%) | 19 (39.6%) | 48 | |
| Age at registration (years) | 0.182 | |||
| Mean (SD) | 48.8 (10.3) | 50.5 (10.7) | 49.2 (10.4) | |
| Median | 49.0 | 49.0 | 49.0 | |
| Range | (24.0–79.0) | (26.0–75.0) | (24.0–79.0) | |
| Racial group | 0.931 | |||
| Missing | 15 | 7 | 22 | |
| Asian | 15 (71.4%) | 6 (28.6%) | 21 | |
| Black | 67 (77.0%) | 20 (23.0%) | 87 | |
| Other | 5 (71.4%) | 2 (28.6%) | 7 | |
| White | 309 (76.9%) | 93 (23.1%) | 402 | |
| Ethnicity | 0.491 | |||
| Missing | 34 | 20 | 54 | |
| Hispanic/Latino | 36 (81.8%) | 8 (18.2%) | 44 | |
| Non-Hispanic | 341 (77.3%) | 100 (22.7%) | 441 | |
| Tumor subtype | ||||
| HER2+ | 163 (73.8%) | 58 (26.2%) | 221 | 0.261 |
| TNBC | 248 (78.0%) | 70 (22.0%) | 318 | |
| Clinical stage | <0.00011 | |||
| 2 | 291 (82.0%) | 64 (18.0%) | 355 | |
| 3 | 120 (65.2%) | 64 (34.8%) | 184 | |
| Clinical tumor size (cm) | 0.00192 | |||
| N | 404 | 123 | 527 | |
| Mean (SD) | 4.5 (2.5) | 5.5 (3.1) | 4.8 (2.7) | |
| Median | 4.0 | 5.0 | 4.0 | |
| Range | (0.0–22.0) | (0.0–16.0) | (0.0–22.0) | |
| Clinical T category | 0.00161 | |||
| Missing | 9 | 5 | 14 | |
| 1 | 20 (69.0%) | 9 (31.0%) | 29 | |
| 2 | 265 (82.3%) | 57 (17.7%) | 322 | |
| 3 | 105 (67.3%) | 51 (32.7%) | 156 | |
| 4 | 12 (66.7%) | 6 (33.3%) | 18 | |
| Clinical N category | <0.00011 | |||
| 0 | 214 (88.8%) | 27 (11.2%) | 241 | |
| 1 | 157 (66.2%) | 80 (33.8%) | 237 | |
| 2 | 33 (67.3%) | 16 (32.7%) | 49 | |
| 3 | 7 (58.3%) | 5 (41.7%) | 12 | |
| Tumor grade | 0.401 | |||
| Missing | 21 | 12 | 33 | |
| High | 309 (78.4%) | 85 (21.6%) | 394 | |
| Intermediate | 73 (72.3%) | 28 (27.7%) | 101 | |
| Low | 8 (72.7%) | 3 (27.3%) | 11 | |
| Breast surgery | 0.0481 | |||
| Missing | 0 | 1 | 1 | |
| Lumpectomy | 203 (80.2%) | 50 (19.8%) | 253 | |
| Mastectomy | 208 (73.0%) | 77 (27.0%) | 285 | |
| Axillary Surgery | <0.00011 | |||
| Missing | 70 | 7 | 77 | |
| SLNB | 124 (91.9%) | 11 (8.1%) | 135 | |
| ALND | 217 (66.4%) | 110 (33.6%) | 327 | |
| Breast outcome | <0.00011 | |||
| Breast RD | 166 (60.1%) | 110 (39.9%) | 276 | |
| Breast pCR | 245 (93.2%) | 18 (6.8%) | 263 | |
1
Chi-Square
2
Kruskal Wallis